The combination of anti-PD-L1 and anti-Ly6G therapies disrupted this barrier, thereby facilitating the infiltration of more cytotoxic CD8+ T cells into the tumor tissue to target tumor cells. This evidence concerns the gene CD8A and neoplasm.